251 related articles for article (PubMed ID: 20197018)
1. Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
Pérez-Segura P; Bodas A; Sereno M; Martínez-Amores B; Olivera H; Díaz S; López-Asenjo JA; Puente J; Maluenda C; Díaz-Rubio E
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):230-2. PubMed ID: 20197018
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.
Huang K; Gutierrez LP; Bülow S; Gallinger S; Castells A; Eagle CJ; Church JM
Fam Cancer; 2011 Jun; 10(2):303-8. PubMed ID: 21359561
[TBL] [Abstract][Full Text] [Related]
6. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
Bresalier RS
Gastroenterology; 2000 Dec; 119(6):1797-8. PubMed ID: 11113106
[No Abstract] [Full Text] [Related]
8. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Dovizio M; Tacconelli S; Ricciotti E; Bruno A; Maier TJ; Anzellotti P; Di Francesco L; Sala P; Signoroni S; Bertario L; Dixon DA; Lawson JA; Steinhilber D; FitzGerald GA; Patrignani P
J Pharmacol Exp Ther; 2012 Apr; 341(1):242-50. PubMed ID: 22262921
[TBL] [Abstract][Full Text] [Related]
9. Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
van Heumen BW; Roelofs HM; te Morsche RH; Nagengast FM; Peters WH
Orphanet J Rare Dis; 2013 Nov; 8():181. PubMed ID: 24245549
[TBL] [Abstract][Full Text] [Related]
10. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
13. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
14. Nine-year follow-up of a patient with attenuated familial adenomatous polyposis treated with cyclo-oxygenase-2 inhibitors.
Ferguson CB; Porter KG; Murphy SJ
Scand J Gastroenterol; 2008; 43(12):1534-6. PubMed ID: 18609144
[TBL] [Abstract][Full Text] [Related]
15. [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
Wullen B; Mühlhöfer A; Zoller WG
Z Gastroenterol; 2001 Apr; 39(4):335-7. PubMed ID: 11367984
[No Abstract] [Full Text] [Related]
16. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Manzano A; Pérez-Segura P
ScientificWorldJournal; 2012; 2012():327341. PubMed ID: 22649288
[TBL] [Abstract][Full Text] [Related]
19. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
